NFL Biosciences

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:55:00 11/12/2025 GMT			5-day change	1st Jan Change
1.100 ^EUR	+4.56%		+6.80%	-44.16%

12-08	NFL Biosciences SA Obtains Complementary Characterization Results for NFL-101, its First-In-Class Drug Candidate for Smoking Cessation, and Prepares A New Patent Application	CI
10-27	The new silk road of optimism

NFL Biosciences Kicks Off Nearly EUR3 Million Fundraising

Published on 01/31/2023 at 04:39 am GMT - Modified on 01/31/2023 at 04:40 am GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about NFL Biosciences

12-08	NFL Biosciences SA Obtains Complementary Characterization Results for NFL-101, its First-In-Class Drug Candidate for Smoking Cessation, and Prepares A New Patent Application	CI
10-27	The new silk road of optimism
10-20	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
09-24	The Fed Can't Save Everyone
09-01	Nfl Biosciences Announces the Publication of the Results of Its Phase 2 Clinical Trial Cesto Ii Evaluating Nfl-101 in Smoking Cessation in Nicotine & Tobacco Research	CI
08-06	Tech Pillars Under Pressure
07-28	NFL Biosciences Announces Scientific Collaboration with Mclean Hospital to Further Investigate the Mechanism of Action of NFL-101	CI
07-22	NFL Biosciences Secures New EUR1 Million Financing	MT
07-22	NFL Biosciences SA Secures ?1.2 Million in Medium-Term Non-Dilutive Financing from Three Partners	CI
07-21	NFL Biosciences SA announced that it expects to receive ?0.6 million in funding	CI
07-03	NFL Biosciences Appoints Yannick Plétan as Chief Medical Officer	CI
05-23	NFL Biosciences Raises EUR3 Million Via Share Issue	MT
02-04	NFL Biosciences: stock rises after positive results
12-05	NFL Biosciences: industrial organization set up
02/10/24	NFL BIOSCIENCES : Invest Securities reduces its target
15/07/24	NFL Biosciences: potential in smoking cessation confirmed
15/07/24	NFL BIOSCIENCES : Invest Securities raises its target
29/05/24	NFL Biosciences: study with CEA presented at congress
21/05/24	NFL Biosciences receives positive feedback from the FDA
12/04/24	Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin...
12/04/24	NFL Biosciences: successful capital increase
12/04/24	NFL Biosciences Raises EUR3 Million for Clinical Trial, Partnerships	MT
30/01/24	NFL Biosciences: success of smoking cessation study
18/07/23	NFL Biosciences Announces Patent Application Filed in the United States for Reducing Alcohol Consumption with NFL-301 & Preparation of a Pre-Ind Application Submission with the FDA	CI
30/06/23	NFL Biosciences: GB Holding raises its stake

NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2024, the company has one product in phase II/III clinical development (NFL-101) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

03-29 - Q4 2025 Earnings Release (Projected)

More about the company